Blood Advances Journal

Overview
Identity
View All

publication venue for

How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines 2021
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate intensity anticoagulation in critically ill patients 2021
Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis. 5:3120-3133. 2021
ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America. 5:3032-3046. 2021
Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context. 5:3047-3052. 2021
Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism. 5:2237-2244. 2021
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. 5:927-974. 2021
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. 5:1081-1091. 2021
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. 5:872-888. 2021
Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. 5:451-458. 2021
von Willebrand disease: proposing definitions for future research.. 5:565-569. 2021
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. 5:280-300. 2021
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. 5:301-325. 2021
A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. 4:6259-6273. 2020
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. 4:5373-5377. 2020
Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. 4:5184-5193. 2020
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. 4:4693-4738. 2020
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. 4:4929-4944. 2020
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). 4:4632-4639. 2020
Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism. 4:4296-4311. 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. 4:3528-3549. 2020
Iron deficiency following bariatric surgery: a retrospective cohort study. 4:3639-3647. 2020
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. 4:3520-3527. 2020
Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. 4:3368-3377. 2020
Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. 4:2962-2966. 2020
Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism. 4:2798-2809. 2020
Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. 4:2557-2566. 2020
Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis. 4:2779-2788. 2020
Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). 4:2460-2467. 2020
Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy. 4:2516-2522. 2020
Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. 4:2351-2365. 2020
A user guide to the American Society of Hematology clinical practice guidelines. 4:2095-2110. 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. 4:2011-2017. 2020
DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. 4:1512-1517. 2020
Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy. 4:1250-1264. 2020
Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. 4:1539-1553. 2020
Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines. 4:953-968. 2020
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. 4:728-739. 2020
A practical approach to evaluating postoperative thrombocytopenia. 4:776-783. 2020
Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. 4:500-513. 2020
2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. 3:3945-3950. 2019
American Society of Hematology 2019 guidelines for immune thrombocytopenia. 3:3829-3866. 2019
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. 3:3898-3944. 2019
American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. 3:3867-3897. 2019
Updated international consensus report on the investigation and management of primary immune thrombocytopenia. 3:3780-3817. 2019
Thrombus stability explains the factor V Leiden paradox: a mouse model. 3:3375-3378. 2019
A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. 3:1638-1646. 2019
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. 3:789-796. 2019
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis. 3:158-167. 2019
American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. 2:3292-3316. 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. 2:3226-3256. 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 2:3360-3392. 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. 2:3257-3291. 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. 2:3198-3225. 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. 2:3317-3359. 2018
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. 2:3193-3195. 2018
Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. 2:3155-3162. 2018
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. 2:1935-1945. 2018
Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development. 2:1998-2011. 2018
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. 2:1806-1806. 2018
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. 2:1449-1458. 2018
Risk of recurrent venous thromboembolism according to baseline risk factor profiles. 2:788-796. 2018
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. 2:529-533. 2018
Designing a successful capacity-building program in a low-income country: the St. Joseph’s Health System–McMaster–Makerere International Outreach Program Collaboration for Uganda. 1:1-4. 2017
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. 1:2414-2420. 2017
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. 1:1827-1838. 2017
Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. 1:1037-1046. 2017
The direct oral anticoagulants: can we finally stop using rat poison?. 1:980-980. 2017
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. 1:772-778. 2017